Branched Chain Amino Acids Are Associated with Insulin Resistance Independent of Leptin and Adiponectin in Subjects with Varying Degrees of Glucose Tolerance by Connelly, Margery A. et al.
 
 
 University of Groningen
Branched Chain Amino Acids Are Associated with Insulin Resistance Independent of Leptin
and Adiponectin in Subjects with Varying Degrees of Glucose Tolerance
Connelly, Margery A.; Wolak-Dinsmore, Justyna; Dullaart, Robin P. F.
Published in:
Metabolic syndrome and related disorders
DOI:
10.1089/met.2016.0145
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Connelly, M. A., Wolak-Dinsmore, J., & Dullaart, R. P. F. (2017). Branched Chain Amino Acids Are
Associated with Insulin Resistance Independent of Leptin and Adiponectin in Subjects with Varying
Degrees of Glucose Tolerance. Metabolic syndrome and related disorders, 15(4), 183-186.
https://doi.org/10.1089/met.2016.0145
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Branched Chain Amino Acids Are Associated with Insulin
Resistance Independent of Leptin and Adiponectin
in Subjects with Varying Degrees of Glucose Tolerance
Margery A. Connelly, PhD, MBA,1 Justyna Wolak-Dinsmore, PhD,1 and Robin P.F. Dullaart, MD, PhD2
Abstract
Background: Branched chain amino acids (BCAA) may be involved in the pathogenesis of insulin resistance
and are associated with type 2 diabetes mellitus (T2DM) development. Adipokines such as leptin and adipo-
nectin influence insulin resistance and reflect adipocyte dysfunction. We examined the extent to which the
association of BCAA with insulin resistance is attributable to altered leptin and adiponectin levels in individuals
with varying degrees of glucose tolerance.
Methods: BCAA were measured by nuclear magnetic resonance, whereas leptin and adiponectin were measured
by immunoassay, in subjects with normal fasting glucose (n = 30), impaired fasting glucose (n = 25), and T2DM
(n = 15). Insulin resistance was estimated by homeostasis model assessment (HOMAir).
Results: BCAA were higher in men than in women (P < 0.001) and tended to be higher in T2DM subjects
(P = 0.10) compared to subjects with normal or impaired fasting glucose. In univariate regression analysis,
BCAA were correlated with HOMAir (r = 0.46; P < 0.001) and inversely with adiponectin (r = -0.53; P < 0.001)
but not with leptin (r = -0.08; P > 0.05). Multivariable linear regression analysis, adjusting for age, sex, T2DM,
and body mass index (BMI), demonstrated that BCAA were positively associated with HOMAir (b= 0.242,
P = 0.023). When BCAA, leptin, and adiponectin were included together, the positive relationship of HOMAir
with BCAA (b= 0.275, P = 0.012) remained significant.
Conclusions: Insulin resistance was associated with BCAA. This association remained after adjusting for age,
sex, T2DM, BMI, as well as leptin and adiponectin. It is unlikely that the relationship of insulin resistance with
BCAA is to a major extent attributable to effects of leptin and adiponectin.
Keywords: branched chain amino acids, nuclear magnetic resonance spectroscopy, insulin resistance, adipose
tissue dysfunction, type 2 diabetes mellitus
Introduction
Branched chain amino acids (BCAA) have beenshown to be elevated in metabolic disorders associated
with insulin resistance, such as obesity, metabolic syndrome,
and type 2 diabetes mellitus (T2DM).1–4 Potential mecha-
nisms for enhanced circulating BCAA concentrations include
excess dietary consumption, elevated production by gut mi-
crobes, and decreased BCAA catabolism in muscle and adi-
pose tissue.1,3–5 It has been hypothesized that BCAA may in
fact be a causal factor in the development of insulin resistance
and T2DM by contributing to the overload of mitochondria
with lipid substrates, which subsequently leads to mitochon-
drial stress and impaired insulin action.1,3 Consistent with
these observations, BCAA may be predictive of diabetes
development.6–8 BCAA levels are, moreover, responsive to
therapeutic interventions that enhance insulin sensitivity.9
Therefore, measurement of circulating BCAA may be useful
for determining metabolic and adipose tissue dysfunction in
advance of chronic disease development.
It is well known that the adipokines, leptin and adipo-
nectin, are altered in obesity, metabolic syndrome, and
T2DM.10,11 While both adipokines are secreted by adipose
tissue, leptin levels are higher and adiponectin levels are
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lower in obese subjects.12,13 Leptin and adiponectin play key
roles in adipocyte differentiation.14–16 Moreover, the leptin/
adiponectin ratio is related to systemic inflammation and is a
determinant of insulin resistance in nondiabetic individuals,
highlighting the contribution of adipose tissue dysfunction to
the pathogenesis of diminished insulin action.17,18
The aim of this study was to interrogate the extent to which
the potential association of insulin resistance with circulating
BCAA is attributable to altered leptin and adiponectin levels in
individuals with varying degrees of glucose tolerance.
Materials and Methods
Patients
The Medical Ethics Committee of the University Medical
Center Groningen approved the study protocol. Participants,
aged >18 years, were recruited by newspaper advertisement.
Written informed consent was obtained. Glucose tolerance
status was classified as normal fasting plasma glucose (FPG
<5.6 mM), impaired fasting glucose (FPG ‡5.6 and £6.9 mM),
and T2DM (FPG ‡7.0 mM; previously determined non-FPG
‡11.1 mM), according to NCEP-ATPIII criteria and guidelines
from the Dutch College of General Practitioners. T2DM had
been previously diagnosed by general practitioners. Subjects
who used insulin, oral glucose-lowering drugs, lipid-lowering
drugs, or antihypertensive medication were not allowed to
participate in the present study. This was done to avoid con-
founding of medication use on insulin resistance and other
relevant variables. From an initially selected group of 103
subjects, 33 were excluded because they used glucose-lowering
drugs or antihypertensives. Subjects had been given dietary
advice as part of their diabetic treatment; their nutrient intake
was not standardized before entry in the study. Current smokers
were also excluded, as were subjects with history of cardio-
vascular or chronic kidney disease, liver or thyroid dysfunction.
All participants were evaluated after an overnight fast.
Blood pressure was measured as described.18 Body mass
index (BMI; kg/m2) was calculated as weight divided by
height squared. Homeostasis model assessment of insulin
resistance (HOMAir) was used to estimate insulin resistance
(fasting insulin (mU/L) · fasting glucose (mM)/22.5).
Laboratory analysis
EDTA plasma was collected and stored at -80C until
analysis. Plasma glucose, total cholesterol, HDL-cholesterol,
triglycerides, insulin, leptin, and adiponectin were assayed as
described.19 Intra-assay and interassay coefficient of varia-
tions (CVs) were <6% and <8%, respectively.
Nuclear magnetic resonance data acquisition
and BCAA signal deconvolution analysis
Nuclear magnetic resonance spectra were acquired using
EDTA plasma on a Vantera Clinical Analyzer as previously
described.20,21 For BCAA analysis, an optimized deconvolu-
tion algorithm was implemented, which simultaneously
models the methyl signals for the lipoproteins, proteins, and
BCAA between 0.718 and 1.02 ppm in the serum spectrum.
Concentrations were determined using non-negative linear
least squares by determining the signal area and multiplying by
particle conversion factors. Intra-assay and interassay CVs for
BCAA were 3.2% and 3.3%, respectively.
Statistical analysis
SPSS (version 23.0; SPSS, Inc., Chicago, IL) was used
for data analysis. Results are expressed as mean – SD or as
median (interquartile range). Variables between the three
groups were compared by ANOVA with the Bonferroni
method to correct for multiple comparisons or by the chi-
square test. Univariate relationships were assessed with
Pearson’s correlation coefficients. Because of skewed dis-
tributions, logarithmically transformed values of HOMAir,
leptin, and adiponectin were used. Multivariable linear re-
gression analyses with a subsequent backward procedure
were carried out to demonstrate the independent relationship
of HOMAir with BCAA, leptin, and adiponectin. Two-sided
P-values <0.05 were considered significant.
Results
Seventy subjects (40 women and 30 men) participated, of
whom 30 had normal fasting glucose, 25 had impaired fast-
ing glucose, and 15 had T2DM (Table 1). BMI did not sig-
nificantly vary across the three glucose tolerance groups
(P = 0.56), but HOMAir was higher in T2DM subjects than in
subjects with normal fasting glucose (P < 0.01). Total choles-
terol (P = 0.05) was slightly lower in T2DM subjects than in
subjects with normal fasting glucose. Plasma leptin and adi-
ponectin levels were not significantly different between the
three groups (P = 0.86 and P = 0.59, respectively). BCAA did
not significantly differ between the three glucose tolerance
categories (P = 0.27), but tended to be higher in T2DM sub-
jects versus the other subjects (P = 0.10). BCAA were higher in
men (452 – 82mM) than in women (372 – 74mM, P < 0.001).
Neither BCAA (P = 0.32) nor leptin (P = 0.80) and adiponectin
(P = 0.22) levels were significantly different between the
groups after adjustment for age and sex.
In univariate analysis carried out in all participants together,
BCAA were associated with HOMAir (r = 0.46, P < 0.001) and
BMI (r = 0.40, P < 0.001), and inversely with adiponectin
(r = -0.53, P < 0.001) but not with leptin (r = -0.08, P > 0.05). In
men, BCAA were correlated positively with HOMAir (r = 0.45,
P = 0.012) and BMI (r = 0.427, P = 0.019), and inversely with
adiponectin (r = -0.554, P = 0.001); the relationship with leptin
was not significant (r = 0.32, P = 0.084). In women, BCAA
were similarly correlated positively with HOMAir (r = 0.457,
P = 0.003), BMI (r = 0.399, P = 0.011), and leptin (r = -0.33,
P = 0.037), and there was also a positive correlation with leptin
(r = 0.33, P = 0.037). Furthermore, in the whole group, HO-
MAir was positively correlated with BMI (r = 0.54, P < 0.001)
as well as with leptin (r = 0.35, P < 0.001) and inversely with
adiponectin (r = -0.41, P < 0.001). No correlation between
leptin and adiponectin was observed (r = 0.06, P > 0.05).
Multivariable linear regression analysis, adjusting for age,
sex, diabetes status, and BMI, demonstrated that HOMAir
was positively associated with BCAA (Table 2, model A).
There was also an independent relationship of HOMAir with
leptin taking account of BMI and adiponectin (Table 2,
model B). Notably, when BCAA, leptin, and adiponectin
were included together in the analyses, the positive rela-
tionships of HOMAir with BCAA and leptin remained
present even independent of BMI (Table 2, model C). A
similar age- and sex-adjusted relationship of HOMAir with
BCAA, taking account of leptin and adiponectin, was found
in multivariable analysis that did not include diabetes status
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(b = 0.370, P = 0.001), BMI (b = 0.275, P = 0.012), or both
(b = 0.332, P = 0.004) (data not shown).
Discussion
As far as we are aware, our study is the first to delineate the
relationship between BCAA and insulin resistance in the
context of adipokines, in particular, leptin and adiponectin. As
expected from previously published literature, our study re-
vealed a fairly strong relationship between BCAA and insulin
resistance among subjects with varying degrees of glucose
tolerance. Notably, in all subjects combined, BCAA were
univariately correlated with insulin resistance, BMI, and adi-
ponectin but not with leptin, even though leptin and adipo-
nectin were each associated with insulin resistance. Our finding
that insulin resistance was still related to BCAA, independent
of diabetes status, BMI, leptin, and adiponectin, raises the
possibility that BCAA and these adipokines may act, in part, by
different mechanisms on insulin-mediated glucose metabo-
lism. Our findings also suggest that adipose tissue dysfunction,
as reflected by plasma levels of leptin and adiponectin, is un-
likely the main pathogenic mechanism explaining the rela-
tionship of insulin resistance with circulating BCAA.
Obesity-associated plasma BCAA elevation levels have
been proposed to indicate BCAA dysmetabolism, resulting in
abnormal mitochondrial function, which in turn contributes to
insulin resistance.3,4 Yet, it is still possible that increased cir-
culating BCAA levels represent a mere marker of impaired
insulin action.3 Of further interest, it is well recognized that
leptin- and adiponectin-mediated processes are involved in the
pathogenesis of insulin resistance as well; although the con-
tributing molecular mechanisms appear to be at least, in part,
different from that exerted by BCAA.3,12,14,17 Importantly,
leptin and adiponectin modulate low-grade inflammation and
hence are thought to reflect adipose tissue dysfunction.14,16–18
Together with a direct effect of leucine, which makes part of
the BCAA measurement in this study, on leptin metabolism,3
the well-documented relationships of insulin resistance with
circulating BCAA, leptin, and adiponectin levels1,10,12 led us
to explore the extent to which the relationship of insulin re-
sistance with BCAA was explained by plasma levels of these
adipokines. Our study shows that the relationship of insulin
resistance with leptin and adiponectin is independent of BMI,
in agreement with the role of these adipokines in adipose tissue
dysfunction.17,18 A novel finding of the current report is that
Table 2. Multivariable Linear Regression
Analysis Demonstrating Relationships of Insulin
Resistance (Homeostasis Model Assessment ) with
Plasma Branched Chain Amino Acids, Leptin,
and Adiponectin in 70 Subjects with Varying
Degrees of Glucose Tolerance (Normal
Fasting Glucose, n = 30; Impaired Fasting
Glucose, n = 25; Type 2 Diabetes Mellitus, n = 15)
Model A Model B Model C
b P b P b P
Age 0.005 0.96 0.038 0.72 0.016 0.88
Sex (men/
women)
-0.058 0.60 0.268 0.13 0.223 0.20
0.574 <0.001 0.384 0.007
T2DM
(yes/no)
0.252 0.015 0.280 0.005 0.266 0.007
0.252 0.011 0.320 0.001 0.281 0.003
BMI 0.411 <0.001 0.213 0.089 0.158 0.22
0.417 <0.001
BCAA 0.271 0.026 0.196 0.099
0.242 0.023 0.275 0.012
Leptin 0.463 0.007 0.466 0.006
0.744 <0.001 0.640 <0.001
Adiponectin -0.210 0.075 -0.146 0.232
Variables with which HOMAir is independently associated by
multivariable linear regression analysis with a subsequent backward
procedure are shown in bold. Model A includes age, sex, T2DM,
BMI, and BCAA. Model B includes age, sex, T2DM, BMI, leptin,
and adiponectin. Model C includes age, sex, T2DM, BMI, BCAA,
leptin, and adiponectin.
b, standardized regression coefficient; BMI, body mass index.
Table 1. Clinical Characteristics, Insulin Resistance (Homeostasis Model Assessment), Plasma
Leptin, Adiponectin, and Branched Chain Amino Acids in 70 Subjects with Varying Degrees
of Glucose Tolerance (Normal Fasting Glucose, n = 30; Impaired Fasting Glucose,
n = 25; Type 2 Diabetes Mellitus, n = 15)
NFG (n = 30) IFG (n = 25) T2DM (n = 15) ANOVA P value
Age (years) 52 – 9 56 – 9 61 – 9a 0.008
Sex (men/women) 11/19 11/14 8/7 0.56
Systolic blood pressure (mmHg) 129 – 19 131 – 21 139 – 20 0.29
Diastolic blood pressure (mmHg) 84 – 14 80 – 8 81 – 6 0.31
Body mass index (kg/m2) 25.9 – 4.6 25.0 – 3.0 26.4 – 5.2 0.56
Glucose (mM) 5.3 – 0.5 6.0 – 0.3 8.3 – 2.1a,b <0.001
Insulin (mU/L) 6.3 (4.3–8.6) 6.0 (4.6–8.3) 6.1 (4.5–9.7) 0.60
HOMAir, (mU/L) · (mM)/22.5 1.5 (1.0–2.1) 1.7 (1.2–2.4) 2.3 (1.6–3.8)a 0.007
Total cholesterol (mM) 5.8 – 1.1 5.8 – 0.8 5.0 – 0.9c 0.02
HDL cholesterol (mM) 1.5 – 0.4 1.6 – 0.4 1.6 – 0.5 0.54
Triglycerides (mM) 1.3 (0.8–2.0) 1.3 (0.9–1.9) 1.6 (0.8–2.3) 0.97
Leptin (mg/L) 6.8 (3.2–22.7) 5.9 (3.3–23.7) 5.9 (1.3–31.4) 0.86
Adiponectin (mg/L) 22.7 (15.0–48.1) 21.3 (16.2–40.7) 17.0 (12.4–33.0) 0.59
BCAA (mM) 397 – 92 398 – 73 439 – 95 0.27
Data in mean – SD or in median (interquartile range).
aP < 0.01 from subjects with NFG.
bP < 0.05 from subjects with IFG.
cP £ 0.05 from subjects with NFG.
BCAA, branched chain amino acids; HOMAir, homeostasis model assessment; IFG, impaired fasting glucose; NFG, normal fasting
glucose; T2DM, type 2 diabetes mellitus.
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the relationship of insulin resistance with BCAA was inde-
pendent of leptin and adiponectin also when taking BMI into
account. Assuming that leptin and adiponectin are valid bio-
markers of altered adipose tissue functionality, this result
agrees with the hypothesis that the insulin resistance-BCAA
association is not to a considerable extent driven by adipose
tissue dysfunction. In view of the emerging role of the hepa-
tokine, fetuin-A, in the pathogenesis of insulin resistance,22
and the observation that fetuin-A is associated with incident
diabetes, even independent of adiposity measures,23 it is rel-
evant to put the role of BCAA in diabetes development in the
context of hepatokine dysregulation in future studies.
Several methodological issues should be considered. The
cross-sectional design does not allow us to address the nature
of the observed relationships. We cannot exclude the possi-
bility that elevated BCAA are contributing to or that they are
a result of insulin resistance and altered adipose tissue
function. In addition, a limited number of T2DM subjects
were included whose metabolic control was generally suffi-
cient. Moreover, BMI did not significantly vary across the
glucose tolerance groups. Participants did not receive hypo-
glycemic drugs or antihypertensive medication, thus avoiding
confounding due to drug effects on insulin resistance. This
likely explains why BCAA only tended to be higher in sub-
jects with T2DM compared to those who were normogly-
cemic or had impaired fasting glucose. Lipid-lowering drugs
were not used, explaining why subjects with only mild lipid
abnormalities preferentially participated.
In conclusion, BCAA are associated positively with in-
sulin resistance even when taking account of leptin and
adiponectin diabetes and adiposity. This suggests that the
relationship of insulin resistance with BCAA is at least, in
part, independent of adipose tissue dysfunction.
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